Financing ·
Verastem Oncology reported second quarter 2026 financial results and announced a non-dilutive royalty financing…
VSTMVerastem, Inc.
Verastem Oncology reported second quarter 2026 financial results and announced a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing on August 28, 2026. The company also received a $15 million milestone payment from Secura Bio for COPIKTRA sales exceeding $200 million. Net product revenue for AVMAPKI FAKZYNJA CO-PACK reached $25.1 million in Q2 2026, up from $2.1 million in the prior year period, bringing total revenue to $40.1 million. The company ended the quarter with $136.4 million in cash and investments, rising to a pro forma $201.4 million after the Oberland closing and milestone receipt. Clinically, Verastem dosed the first patients in all three TARGET-D Phase 2 registration-directed trials for VS-7375 across pancreatic, lung, and colorectal cancers. The biopharmaceutical company develops and commercializes medicines for RAS/MAPK pathway-driven cancers.